Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents

Bone

Volumn 95, Issue , 2017, Pages 11-19

  Vlot, Mariska C ^a   Klink, Daniel T ^a   den Heijer, Martin ^a   Blankenstein, Marinus A ^a   Rotteveel, Joost ^a   Heijboer, Annemieke C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone mineral density; Bone turnover markers; GnRHa; Puberty; Transgender

Indexed keywords

ESTRADIOL; GONADORELIN; OSTEOCALCIN; TESTOSTERONE; TRIPTORELIN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; SEX HORMONE;

ADOLESCENT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; DISTRESS SYNDROME; DYSPHORIA; FEMALE; FEMORAL NECK; HORMONAL THERAPY; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MALE TO FEMALE TRANSGENDER; PUBERTY; SCORING SYSTEM; TRANSGENDER; BLOOD; CLINICAL TRIAL; LUMBAR VERTEBRA; METABOLISM; PATHOPHYSIOLOGY;

ADOLESCENT; BIOMARKERS; BONE DENSITY; BONE REMODELING; FEMALE; FEMUR NECK; GONADAL HORMONES; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOCALCIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; PUBERTY; TRANSGENDER PERSONS;

EID: 84995486953     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2016.11.008     Document Type: Article

References (39)

1. [1] van Coeverden, S.C., Netelenbos, J.C., Roos, J.C., de Ridder, C.M., Delemarre-van de Waal, H.A., Reference values for bone mass in Dutch white pubertal children and their relation to pubertal maturation characteristics. Ned. Tijdschr. Geneeskd. 145:38 (Sep 22 2001), 1851–1856.
2. [2] Yilmaz, D., Ersoy, B., Bilgin, E., Gumuser, G., Onur, E., Pinar, E.D., Bone mineral density in girls and boys at different pubertal stages: relation with gonadal steroids, bone formation markers, and growth parameters. J. Bone Miner. Metab. 23:6 (2005), 476–482.
3. [3] de Vries, A.L., Steensma, T.D., Doreleijers, T.A., Cohen-Kettenis, P.T., Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J. Sex. Med. 8:8 (Aug 2011), 2276–2283.
4. [4] Cohen-Kettenis, P.T., Schagen, S.E., Steensma, T.D., de Vries, A.L., Delemarre-van de Waal, H.A., Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up. Arch. Sex. Behav. 40:4 (Aug 2011), 843–847.
5. [5] Rosenthal, S.M., Approach to the patient: transgender youth: endocrine considerations. J. Clin. Endocrinol. Metab. 99:12 (Dec 2014), 4379–4389.
6. [6] Klink, D., Caris, M., Heijboer, A.C., Rotteveel, J., Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. J. Clin. Endocrinol. Metab. 100:2 (Feb 2015), E270–E275.
7. [7] Antoniazzi, F., Zamboni, G., Bertoldo, F., Lauriola, S., Tato, L., Bone development during GH and GnRH analog treatment. Eur. J. Endocrinol. 151:Suppl. 1 (Aug 2004), S47–S54.
8. [8] Van Caenegem, E., Wierckx, K., Taes, Y., Dedecker, D., Van de Peer, F., Toye, K., et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J. Clin. Endocrinol. Metab. 97:7 (Jul 2012), 2503–2511.
9. [9] Van Caenegem, E., Wierckx, K., Taes, Y., Schreiner, T., Vandewalle, S., Toye, K., et al. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study [ENIGI]. Eur. J. Endocrinol. 172:2 (Feb 2015), 163–171.
10. [10] Blumsohn, A., Hannon, R.A., Wrate, R., Barton, J., al-Dehaimi, A.W., Colwell, A., et al. Biochemical markers of bone turnover in girls during puberty. Clin. Endocrinol. 40:5 (May 1994), 663–670.
11. [11] Rauchenzauner, M., Schmid, A., Heinz-Erian, P., Kapelari, K., Falkensammer, G., Griesmacher, A., et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J. Clin. Endocrinol. Metab. 92:2 (Feb 2007), 443–449.
12. [12] Bayer, M., Reference values of osteocalcin and procollagen type I N-propeptide plasma levels in a healthy Central European population aged 0–18 years. Osteoporos. Int. 25:2 (Feb 2014), 729–736.
13. [13] American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. fourth ed., 2000, American Psychiatric Association, Arlington, VA, 576–581.
14. [14] Greulich, W.W., Pyle, S.I., Radiographic Atlas of Skeletal Development of the Hand and Wrist. second ed., 1959, Stanford University Press, Stanford.
15. [15] Ward, K.A., Ashby, R.L., Roberts, S.A., Adams, J.E., Zulf, M.M., UK reference data for the Hologic QDR discovery dual-energy x ray absorptiometry scanner in healthy children and young adults aged 6–17 years. Arch. Dis. Child. 92:1 (Jan 2007), 53–59.
16. [16] Baroncelli, G.I., Saggese, G., Critical ages and stages of puberty in the accumulation of spinal and femoral bone mass: the validity of bone mass measurements. Horm. Res. 54:Suppl. 1 (2000), 2–8.
17. [17] Amama, E.A., Taga, M., Minaguchi, H., The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover. J. Clin. Endocrinol. Metab. 83:2 (Feb 1998), 333–338.
18. [18] van der Sluis, I.M., Boot, A.M., Krenning, E.P., Drop, S.L., de Muinck Keizer-Schrama, S.M., Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J. Clin. Endocrinol. Metab. 87:2 (Feb 2002), 506–512.
19. [19] Mueller, A., Dittrich, R., Binder, H., Kuehnel, W., Maltaris, T., Hoffmann, I., et al. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Eur. J. Endocrinol. 153:1 (Jul 2005), 107–113.
20. [20] Szulc, P., Seeman, E., Delmas, P.D., Biochemical measurements of bone turnover in children and adolescents. Osteoporos. Int. 11:4 (2000), 281–294.
21. [21] Yang, L., Grey, V., Pediatric reference intervals for bone markers. Clin. Biochem. 39:6 (Jun 2006), 561–568.
22. [22] Goldray, D., Weisman, Y., Jaccard, N., Merdler, C., Chen, J., Matzkin, H., Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl [D-Trp6-GnRH]. J. Clin. Endocrinol. Metab. 76:2 (Feb 1993), 288–290.
23. [23] Mittan, D., Lee, S., Miller, E., Perez, R.C., Basler, J.W., Bruder, J.M., Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J. Clin. Endocrinol. Metab. 87:8 (Aug 2002), 3656–3661.
24. [24] Delemarre-van de Waal, H., Cohen-Kettenis, P.T., Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur. J. Endocrinol. 155 (2006), S131–S137.
25. [25] van Kesteren, P., Lips, P., Gooren, L.J., Asscheman, H., Megens, J., Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin. Endocrinol. 48:3 (Mar 1998), 347–354.
26. [26] Lehtonen-Veromaa, M., Mottonen, T., Irjala, K., Nuotio, I., Leino, A., Viikar, J., A 1-year prospective study on the relationship between physical activity, markers of bone metabolism, and bone acquisition in peripubertal girls. J. Clin. Endocrinol. Metab. 85:10 (Oct 2000), 3726–3732.
27. [27] Tracz, M.J., Sideras, K., Bolona, E.R., Haddad, R.M., Kennedy, C.C., Uraga, M.V., et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J. Clin. Endocrinol. Metab. 91:6 (Jun 2006), 2011–2016.
28. [28] van Coeverden, S.C., Netelenbos, J.C., de Ridder, C.M., Roos, J.C., Popp-Snijders, C., Delemarre-van de Waal, H.A., Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin. Endocrinol. 57:1 (Jul 2002), 107–116.
29. [29] Russell, M., Breggia, A., Mendes, N., Klibanski, A., Misra, M., Growth hormone is positively associated with surrogate markers of bone turnover during puberty. Clin. Endocrinol. 75:4 (Oct 2011), 482–488.
30. [30] Lapauw, B., Taes, Y., Simoens, S., Van Caenegem, E., Weyers, S., Goemaere, S., et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone 43:6 (Dec 2008), 1016–1021.
31. [31] van der Sluis, I.M., de Ridder, M.A., Boot, A.M., Krenning, E.P., de Muinck Keizer-Schrama, S.M., Reference data for bone density and body composition measured with dual energy X-ray absorptiometry in white children and young adults. Arch. Dis. Child. 87:4 (Oct 2002), 341–347.
32. [32] Kikuchi, T., Hashimoto, N., Kawasaki, T., Kataoka, S., Takahashi, H., Uchiyama, M., Plasma levels of carboxy terminal propeptide of type I procollagen and pyridinoline cross-linked telopeptide of type I collagen in healthy school children. Acta Paediatr. 87:8 (Aug 1998), 825–829.
33. [33] Van Caenegem, E., Taes, Y., Wierckx, K., Vandewalle, S., Toye, K., Kaufman, J.M., et al. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone 54:1 (May 2013), 92–97.
34. [34] Van Caenegem, E., Wierckx, K., Taes, Y., Schreiner, T., Vandewalle, S., Toye, K., et al. Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study. Osteoporos. Int. 26:1 (Jan 2015), 35–47.
35. [35] Shim, K.S., Pubertal growth and epiphyseal fusion. Ann. Pediatr. Endocrinol. Metab. 20:1 (Mar 2015), 8–12.
36. [36] Boot, A.M., de Ridder, M.A., van der Sluis, I.M., Krenning, E.P., Keizer-Schrama, S.M., Peak bone mineral density, lean body mass and fractures. Bone 46:2 (Feb 2010), 336–341.
37. [37] Turner, A., Chen, T.C., Barber, T.W., Malabanan, A.O., Holick, M.F., Tangpricha, V., Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects. Clin. Endocrinol. 61:5 (Nov 2004), 560–566.
38. [38] Ruetsche, A.G., Kneubuehl, R., Birkhaeuser, M.H., Lippuner, K., Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study. Osteoporos. Int. 16:7 (Jul 2005), 791–798.
39. [39] Smith, K.P., Madison, C.M., Milne, N.M., Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults. Pharmacotherapy 34:12 (Dec 2014), 1282–1297.